Episode 109: Podcasting for Patients – Adam Cifu’s Latest Venture

Headshot of Adam Cifu for a Podcast Episode

Episode 109: Podcasting for Patients – Adam Cifu’s Latest Venture

Returning to the show is Adam Cifu, MD, University of Chicago, to tell us about his exciting new podcast venture. “The Clinical Excellence Podcast” is dedicated to discussing issues with clinicians, patients, and researchers studying the doctor-patient relationship. Dr. Cifu shares the tricky conversations that doctors and patients have (eg, terminating patient relationships, burnout, second opinions, caring for colleagues, and others), how those will be featured on the podcast, topics that may or may not be off limits, and other avenues of discussions you can expect as a listener.

Related Resources

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More